Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
about
The role of transgenic mouse models in carcinogen identificationEvaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.Stem cell proliferation patterns as an alternative for in vivo prediction and discrimination of carcinogenic compounds.Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse.Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice.Improving prediction of carcinogenicity to reduce, refine, and replace the use of experimental animals.Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs.The use of genetically modified mice in cancer risk assessment: challenges and limitations.Regulatory Forum Opinion Piece*: The Value of Publishing Negative Scientific Study Data.Biomarkers of cancer risk and therapeutic benefit: new technologies, new opportunities, and some challenges.A tiered approach to systemic toxicity testing for agricultural chemical safety assessment.Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment: technical progress or cycle of regulatory capture?An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.Best practices for clinical pathology testing in carcinogenicity studies.Twenty-six-week oral carcinogenicity study of 3-monochloropropane-1,2-diol in CB6F1-rasH2 transgenic mice.Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.The 26-week Tg.rasH2 mice carcinogenicity studies: microscopic examination of only select tissues in low- and mid-dose groups.Toxicity and carcinogenicity studies of chlorpromazine hydrochloride and p-cresidine in the p53 heterozygous mouse model.Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.Investigations of clofibrate in alternative carcinogenicity models.Evaluation of the carcinogenic potential of clofibrate in the p53+/- mouse.Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration--part I.Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II.Studies evaluating the utility of N-methyl-N-nitrosourea as a positive control in carcinogenicity studies in the p53+/- mouse.A 26-week carcinogenicity study of 2-amino-3-methylimidazo[4,5-f]quinoline in rasH2 mice.An integrative test strategy for cancer hazard identification.A one-year neonatal mouse carcinogenesis study of quinacrine dihydrochloride.
P2860
Q24814156-7ADB6050-DF59-4185-8A37-0BC287BB12A1Q33203784-5E5D4D77-5CF4-4EE0-8AE2-FF790E1C1AFCQ33628796-4574961E-E3B3-4A79-8213-5C5F7D701BACQ34463834-1A7A0333-077D-43C0-B7D3-2890197DCDADQ34549812-6F5D3FDB-D2AE-4885-9863-D153998700C2Q35244653-054CCD5B-50A2-4DCE-A7DB-AA56BE3609B2Q35621829-009FD5D3-C9D0-47B8-9DA2-F970DBFBF3A4Q35688431-D100B8B9-11AF-4079-9DA4-D83F4326F996Q35744739-ACFF5065-30B7-4879-945C-E71045A53459Q35812523-86201F11-C9A1-4E3A-B012-96F65BE8F12BQ36481766-B9975D4B-570D-41A2-8CBB-FA2305F662FCQ37187425-7EF72334-FCEB-4A4B-B66D-66674C8771B4Q37628343-AA863CFE-562B-48C3-A5EF-D45C34473B2BQ37633279-B6B9C211-011A-4E7F-AD7A-16F471FFE637Q37795414-A1785FF9-AE8E-45A3-955B-C381BD7A972AQ37836198-34A274E2-05EA-4384-A9AB-2D5CF6005A7BQ38415892-2A01C5DA-C948-4D96-ADC8-731D2AC73FBEQ38965124-4DCF9CC8-F4B4-4B72-BA6F-BB3A309162D0Q44115170-B8376714-3C8C-4C91-95AC-250F2056A967Q44269651-7EB80758-7876-4215-BD2D-0803D073D3A7Q44404169-ED871AB0-63D2-4B1D-8227-1AF37C31A9EDQ46781510-6D27B7B4-453A-4F32-87BA-7C4D220700CCQ46781515-E3EC522E-C696-4861-8196-440F6D975DBFQ46781520-D614D723-D52F-469F-A953-F611F48D6D63Q46781523-788D99FA-4A54-44F0-8705-DDF4B2504D31Q46781526-8DC31DB9-517E-40B0-981B-DA436E9C334EQ46781535-FD900AB1-8D4A-4BDA-962D-81ECEA205B02Q46990423-217B60DF-47CF-4DB0-AC53-2E799D507E66Q50856445-797FD161-F95C-480D-BE23-BAF6E2EC44D6Q51811785-92C2F3F1-20E1-4741-AD6C-B1AD4307005F
P2860
Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment. International Life Sciences Institute.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Background and framework for I ...... ional Life Sciences Institute.
@ast
Background and framework for I ...... ional Life Sciences Institute.
@en
Background and framework for I ...... ional Life Sciences Institute.
@nl
type
label
Background and framework for I ...... ional Life Sciences Institute.
@ast
Background and framework for I ...... ional Life Sciences Institute.
@en
Background and framework for I ...... ional Life Sciences Institute.
@nl
prefLabel
Background and framework for I ...... ional Life Sciences Institute.
@ast
Background and framework for I ...... ional Life Sciences Institute.
@en
Background and framework for I ...... ional Life Sciences Institute.
@nl
P1476
Background and framework for I ...... ional Life Sciences Institute.
@en
P2093
D E Robinson
J S MacDonald
P356
10.1080/019262301753178438
P407
P478
P577
2001-01-01T00:00:00Z